Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients

被引：12
作者：
Gozzetti, Alessandro [1 ]
Bacchiarri, Francesca [1 ]
Sammartano, Vincenzo [1 ]
Defina, Marzia [1 ]
Sicuranza, Anna [1 ]
Mecacci, Bianca [1 ]
Zappone, Elisabetta [1 ]
Cencini, Emanuele [1 ]
Fabbri, Alberto [1 ]
Raspadori, Donatella [1 ]
Bocchia, Monica [1 ]
机构：
[1] Univ Siena, Azienda Osped Univ Senese, Hematol Unit, Siena, Italy
来源：
FRONTIERS IN ONCOLOGY | 2020年 / 10卷
关键词：
Daratumumab; multiple myeloma; rapid infusion; safety; efficacy; MINIMAL RESIDUAL DISEASE; OPEN-LABEL; DEXAMETHASONE; LENALIDOMIDE; MONOTHERAPY; MULTICENTER; BORTEZOMIB; RITUXIMAB; SURVIVAL; THERAPY;
D O I：
10.3389/fonc.2020.570187
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Multiple myeloma survival has significantly improved in recent years, due to novel agents that are available for treatment. The anti-CD38 monoclonal antibody Daratumumab is particularly efficient for patients with relapse/refractory disease, and many studies have shown its unprecedented efficacy also as a first treatment. However, to avoid the incidence of infusion reactions, long infusion schedules of 8 h at first dose and 4 h in the following doses are required, which can reduce the compliance of patients and health care professionals. A reduced infusion time of 90 min has been reported previously, but data are missing on the prolonged safety of this over time as well as the efficacy of this approach. In this work, we investigate the safety of 484 rapid Daratumumab infusions given early after the second dose over a 22 months period in 39 myeloma patients.
引用
收藏
页数：6
相关论文
共 25 条
  • [1] [Anonymous], 2020, DARZALEXR DARATUMUMA
  • [2] [Anonymous], 2020, Common Terminology Criteria for Adverse Events version 5.0
  • [3] Ninety-minute daratumumab infusion is safe in multiple myeloma
    Barr, Hallie
    Dempsey, Jessica
    Waller, Allyson
    Huang, Ying
    Williams, Nita
    Sharma, Nidhi
    Benson, Don M.
    Rosko, Ashley E.
    Efebera, Yvonne A.
    Hofmeister, Craig C.
    [J]. LEUKEMIA, 2018, 32 (11) : 2495 - 2497
  • [4] Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
    Chari, Ajai
    Suvannasankha, Attaya
    Fay, Joseph W.
    Arnulf, Bertrand
    Kaufman, Jonathan L.
    Ifthikharuddin, Jainulabdeen J.
    Weiss, Brendan M.
    Krishnan, Amrita
    Lentzsch, Suzanne
    Comenzo, Raymond
    Wang, Jianping
    Nottage, Kerri
    Chiu, Christopher
    Khokhar, Nushmia Z.
    Ahmadi, Tahamtan
    Lonial, Sagar
    [J]. BLOOD, 2017, 130 (08) : 974 - 981
  • [5] Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin
    Cini, Michela
    Zamagni, Elena
    Valdre, Lelia
    Palareti, Gualtiero
    Patriarca, Francesca
    Tacchetti, Paola
    Legnani, Cristina
    Catalano, Lucio
    Masini, Luciano
    Tosi, Patrizia
    Gozzetti, Alessandro
    Cavo, Michele
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2010, 84 (06) : 484 - 492
  • [6] Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
    Dimopoulos, M. A.
    Oriol, A.
    Nahi, H.
    San-Miguel, J.
    Bahlis, N. J.
    Usmani, S. Z.
    Rabin, N.
    Orlowski, R. Z.
    Komarnicki, M.
    Suzuki, K.
    Plesner, T.
    Yoon, S. -S.
    Ben Yehuda, D.
    Richardson, P. G.
    Goldschmidt, H.
    Reece, D.
    Lisby, S.
    Khokhar, N. Z.
    O'Rourke, L.
    Chiu, C.
    Qin, X.
    Guckert, M.
    Ahmadi, T.
    Moreau, P.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (14) : 1319 - 1331
  • [7] Dimopoulos M, 2020, LANCET, V396, P186, DOI 10.1016/S0140-6736(20)30734-0
  • [8] Activity of rituximab monotherapy in refractory splenic marginal zone lymphoma complicated with autoimmune hemolytic anemia
    Fabbri, Alberto
    Gozzetti, Alessandro
    Lazzi, Stefano
    Lenoci, Mariapia
    D'Amuri, Alessandro
    Leoncini, Lorenzo
    Lauria, Francesco
    [J]. CLINICAL LYMPHOMA & MYELOMA, 2006, 6 (06) : 496 - 499
  • [9] Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
    Facon, T.
    Kumar, S.
    Plesner, T.
    Orlowski, R. Z.
    Moreau, P.
    Bahlis, N.
    Basu, S.
    Nahi, H.
    Hulin, C.
    Quach, H.
    Goldschmidt, H.
    O'Dwyer, M.
    Perrot, A.
    Venner, C. P.
    Weisel, K.
    Mace, J. R.
    Raje, N.
    Attal, M.
    Tiab, M.
    Macro, M.
    Frenzel, L.
    Leleu, X.
    Ahmadi, T.
    Chiu, C.
    Wang, J.
    Van Rampelbergh, R.
    Uhlar, C. M.
    Kobos, R.
    Qi, M.
    Usmani, S. Z.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (22) : 2104 - 2115
  • [10] Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma
    Flores-Montero, J.
    Sanoja-Flores, L.
    Paiva, B.
    Puig, N.
    Garcia-Sanchez, O.
    Boettcher, S.
    van der Velden, V. H. J.
    Perez-Moran, J-J
    Vidriales, M-B
    Garcia-Sanz, R.
    Jimenez, C.
    Gonzalez, M.
    Martinez-Lopez, J.
    Corral-Mateos, A.
    Grigore, G-E
    Fluxa, R.
    Pontes, R.
    Caetano, J.
    Sedek, L.
    del Canizo, M-C
    Blade, J.
    Lahuerta, J-J
    Aguilar, C.
    Barez, A.
    Garcia-Mateo, A.
    Labrador, J.
    Leoz, P.
    Aguilera-Sanz, C.
    San-Miguel, J.
    Mateos, M-V
    Durie, B.
    van Dongen, J. J. M.
    Orfao, A.
    [J]. LEUKEMIA, 2017, 31 (10) : 2094 - 2103
123